Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
Global Automated Biobanking market size was valued at USD 1.42 billion in 2024. The market is projected to grow from USD 1.58 billion in 2025 to USD 2.87 billion by 2032, exhibiting a CAGR of 7.8% during the forecast period.
Automated biobanking refers to advanced storage systems integrating robotics, temperature control, and data management to preserve biological specimens including blood, DNA, tissues, and cells. These high-throughput solutions are critical for maintaining sample integrity in precision medicine, pharmaceutical research, and disease biomarker discovery while reducing human error through end-to-end automation.
Market expansion is driven by rising biopharmaceutical R&D investments (reaching USD 238 billion globally in 2023), increasing demand for personalized medicine, and government initiatives supporting biobank infrastructure. However, high implementation costs and regulatory complexities present notable challenges. Strategic collaborations are accelerating innovation, such as Thermo Fisher Scientific's 2023 acquisition of PeproTech to enhance sample preparation workflows. Leading participants include Brooks Automation, Hamilton Company, and Thermo Fisher, who collectively hold over 35% market share through integrated cold chain management solutions.
Rising Demand for Precision Medicine and Biobanking
The global automated biobanking market is experiencing significant growth due to increasing demand for precision medicine, which relies heavily on high-quality biospecimens. Over 60% of biobanks are now investing in automation to improve sample integrity and traceability.
Advancements in Automated Storage Technologies
Recent technological advancements in robotic sample handling and cryopreservation systems have enabled biobanks to store over 10 million samples with minimal human intervention. Automated systems reduce errors by approximately 75% compared to manual processes.
The global market for automated biobanking is projected to reach $3.8 billion by 2027, growing at a CAGR of 8.2%
Increased funding for biobanking infrastructure, particularly in North America and Europe, is further accelerating adoption of automation solutions across research institutions and hospitals.
MARKET CHALLENGES
High Initial Investment Costs
Implementation of automated biobanking systems requires substantial capital expenditure, with complete solutions often exceeding $2 million. This creates barriers for small and mid-sized research facilities.
Other Challenges
Regulatory Compliance Complexities
Biobanks must navigate evolving regulations across different regions, requiring continuous updates to automated systems to maintain compliance with standards like ISO 20387 and 21 CFR Part 11.
Data Integration Issues
Many organizations struggle with integrating automated biobanking systems with existing LIMS and EHR platforms, with 40% reporting compatibility challenges during implementation.
Limited Skilled Workforce
The shortage of trained professionals capable of operating and maintaining sophisticated automated biobanking systems is slowing adoption rates, particularly in emerging markets. Specialized training programs remain limited globally.
Expansion in Emerging Markets
Growing healthcare infrastructure in Asia-Pacific regions presents significant opportunities, with countries like China and India investing over $500 million annually in biobanking modernization projects.
AI Integration Potential
Artificial intelligence applications in automated biobanking, particularly for sample classification and inventory optimization, could create $1.2 billion in market value by 2030 according to industry analysts.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Large Capacity Systems dominate due to increasing demand from research institutes and pharmaceutical companies handling massive sample volumes. The scalability and high-throughput capabilities make them ideal for long-term biobanking projects. Medium capacity systems show strong growth potential for mid-sized facilities balancing cost and capability. |
| By Application |
|
Biopharmaceutical Companies lead adoption as they require high-quality sample management for drug discovery and development pipelines. Research institutes follow closely, driven by genomic and proteomic studies. Hospitals show increasing implementation for precision medicine initiatives, though adoption is constrained by budget limitations compared to commercial entities. |
| By End User |
|
Commercial Organizations demonstrate the strongest growth momentum, particularly in the biotech sector where automated sample tracking is mission-critical. Academic centers maintain steady demand focused on large-scale research collaborations. Government institutes are expanding capacity to support public health initiatives and biobank networks, though procurement cycles tend to be longer. |
| By Sample Type |
|
Blood Products represent the most widely automated sample type due to standardization advantages and high demand for plasma/serum in research. Human tissue samples are gaining traction with improved cryopreservation techniques. Stem cell biobanking is emerging as a niche growth area, particularly for regenerative medicine applications requiring ultra-low temperature automation. |
| By Automation Level |
|
Fully Automated Systems are becoming the industry standard for core biobanking operations, offering superior sample integrity and processing efficiency. Robotic systems are gaining adoption in high-value applications like clinical trials where precision and traceability are paramount. Semi-automated solutions remain relevant for budget-conscious facilities with lower sample throughput requirements. |
Automated Biobanking Market Leaders Driving Innovation in Sample Management
The global automated biobanking market is dominated by established life science and medical equipment companies. Thermo Fisher Scientific leads the market with its comprehensive portfolio of automated storage systems and sample management solutions. Close competitors include Azenta (formerly Brooks Automation) and Hamilton Company, both offering advanced robotic biobanking platforms with integrated software solutions. These top players account for approximately 60% of the market share.
Several specialist companies are making significant advancements in niche segments. Haier Biomedical has emerged as a strong player in high-capacity storage systems, while SPT Labtech focuses on compact automated solutions for research labs. European manufacturers like IRELEC and Askion Biobanking have developed specialized cold chain automation technologies, particularly for clinical biobanks. Emerging players from Asia, notably MGI Tech, are gaining traction with cost-effective automation options.
List of Key Automated Biobanking Companies ProfiledHaier Biomedical
Azenta (formerly Brooks Automation)
IRELEC
Askion Biobanking
Labplan
Liconic
Tecan Group
B Medical Systems
Panasonic Healthcare
PHC Corporation
The global Automated Biobanking market is projected to grow from $X million in 2024 to $Y million by 2032 at a CAGR of Z%. This growth is driven by increasing demand for precision medicine and biopharmaceutical research. North America currently dominates the market with over 40% share, followed by Europe and Asia-Pacific regions experiencing accelerated adoption.
Other TrendsTechnology Integration and Sample Integrity
Automated systems are increasingly incorporating AI and blockchain for enhanced sample traceability and metadata management. Robotic handling reduces human error, maintaining a 99.8% sample integrity rate in leading biobanks. The shift to -80C automated storage systems has become standard in 78% of new installations.
Application-Specific System DevelopmentBiobanking solutions are becoming more specialized, with 62% of new systems designed for specific applications. Genomics research accounts for 34% of automated biobank usage, while pharmaceutical development represents 28%. Modular systems now allow 30% faster reconfiguration for different sample types compared to conventional units.
Other TrendsCapacity Segmentation and Market Demand
Large capacity systems (>500,000 samples) now represent 45% of the market, growing at 11% CAGR due to population-scale genomics projects. Medium capacity units (50,000-500,000 samples) remain favored by hospital biobanks, holding 38% market share. Emerging economies show 22% higher adoption of small capacity systems for research institutions.
Regulatory Compliance Driving StandardizationStricter sample handling regulations have led to 89% of new biobanks implementing ISO 20387-certified automated systems. The FDA's 2023 guidelines on biological sample integrity have accelerated upgrades, with 67% of US biobanks planning automation investments within two years. EU GDPR compliance costs have dropped 40% through automated audit trail systems.
Regional Analysis: Automated Biobanking MarketEurope
Europe represents the second-largest market for automated biobanking, with strong adoption in the UK, Germany, and Scandinavian countries. The region benefits from coordinated biobanking networks like BBMRI-ERIC that promote standardization and technology sharing. European biobanks emphasize sustainable, energy-efficient automated storage solutions to comply with environmental regulations. National healthcare systems drive adoption in clinical biobanking, while academic consortia fuel research applications. GDPR compliance requirements have accelerated digitization and automation of sample tracking systems across the region, creating consistent market growth.
Asia-Pacific
The Asia-Pacific automated biobanking market is rapidly expanding, led by China, Japan, and Australia. Government initiatives to establish national biobank networks are driving infrastructure investments. Japan's aging population fuels demand for automated biorepositories in precision medicine research. China's growing biotechnology sector and increasing clinical trial activities create strong market potential. However, adoption varies widely between advanced research centers and smaller facilities still transitioning from manual processes. Regional manufacturers are developing cost-effective automation solutions tailored to local market needs.
Latin America
Latin America shows emerging potential in automated biobanking, with Brazil and Mexico as the primary markets. Research collaborations with North American and European institutions are driving technology transfer and standards adoption. Public health initiatives for infectious disease research contribute to demand, though budget constraints limit large-scale automation adoption. The region shows particular interest in mid-range automated systems that balance functionality with affordability, creating opportunities for manufacturers offering tiered product lines.
Middle East & Africa
The MEA region displays growing but uneven adoption of automated biobanking technologies. Gulf Cooperation Council countries lead in healthcare infrastructure investments, including automated hospital-based biobanks. South Africa has established several research biobanks with partial automation. Market growth is constrained by limited local technical expertise and higher reliance on imported systems. However, increasing focus on genomic medicine and pandemic preparedness is generating new interest in automated sample management solutions across the region.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Biotechnology and pharmaceutical companies
Medical research institutions
Healthcare diagnostic manufacturers
Contract research organizations
Investors, analysts, and regulatory bodies
-> Global Automated Biobanking market was valued at USD 1.42 billion in 2024 and is projected to reach USD 2.87 billion by 2032.
-> Key players include Haier Biomedical, Hamilton, SPT Labtech, Azenta (formerly Brooks Automation), and Thermo Fisher Scientific, among others.
-> Key growth drivers include rising biopharmaceutical R&D investments, increasing demand for personalized medicine, and government initiatives supporting biobank infrastructure.
-> North America is a leading region, while Asia-Pacific shows significant growth potential.
-> Emerging trends include integration of robotics, advanced temperature control systems, and enhanced data management solutions.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates